Cartesian Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

August 08, 2025

Simply Wall St

NasdaqGM:RNAC 1 Year Share Price vs Fair Value

Explore Cartesian Therapeutics's Fair Values from the Community and select yours

Cartesian Therapeutics (NASDAQ:RNAC) Second Quarter 2025 Results

Key Financial Results

Net income: US$15.9m (up 65% from 2Q 2024).
EPS: US$0.61 (up from US$0.58 in 2Q 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

earnings-and-revenue-history — NasdaqGM:RNAC Earnings and Revenue History August 8th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Cartesian Therapeutics EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 63%. Earnings per share (EPS) exceeded analyst estimates.

Looking ahead, revenue is forecast to grow 78% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 15% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 6 warning signs for Cartesian Therapeutics you should be aware of, and 2 of them don't sit too well with us.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.